Alder Therapeutics develops allogeneic stem cell therapies, specifically ALD01 for Retinitis Pigmentosa and ALD02 for heart failure, both supported by preclinical data demonstrating efficacy in relevant animal models. These therapies aim to provide treatment options for conditions currently lacking effective solutions, such as mutation-agnostic approaches for inherited blindness and restoration of heart function in heart failure patients.

AnaCardio is developing novel inotropic agents that enhance cardiomyocyte contractility through the ghrelin signaling pathway, aiming to improve cardiac output without increasing oxygen consumption or mortality. This approach addresses the unmet need for effective treatments that target impaired contractility in heart failure patients, potentially improving organ function and quality of life.

EpiEndo Pharmaceuticals is developing glasmacinal, a non-antibiotic macrolide designed to enhance host defense responses and reduce inflammation in patients with chronic respiratory diseases, particularly COPD. This oral treatment aims to decrease the frequency and severity of exacerbations while minimizing the risk of antimicrobial resistance associated with traditional therapies.

Geneos Therapeutics develops personalized therapeutic cancer vaccines (PTCVs) using its proprietary GT-EPIC™ platform, which customizes DNA plasmids to encode up to 40 unique neoantigens from a patient's tumor. This approach aims to enhance the immune response against cancer by generating tumor-infiltrating lymphocytes that target and potentially eradicate cancer cells throughout the body.

Microbiotica develops defined live biotherapeutic products that target specific gut bacteria to improve outcomes in inflammatory bowel disease and cancer immunotherapy. Using a clinic‑led discovery platform, the company identifies microbes linked to patient responses and creates precision microbiome medicines with known mechanisms of action, intended for use alongside standard therapies.

Prokarium utilizes a proprietary strain of bacteria, ZH9, as a microbial immunotherapy platform to target and eliminate tumors while enhancing anti-tumor immunity. The company addresses the high recurrence rates and limited treatment options in bladder cancer, aiming to establish a new standard of care in a market that has seen little innovation for over 30 years.

Strike Pharma develops individualized immunotherapeutic treatments using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology, which targets tumor cells based on the genetic profile of each patient's tumor. This approach enhances therapeutic efficacy while minimizing side effects, addressing the limitations of traditional immunotherapy methods that often overlook efficient drug delivery and stability.

Vitara Biomedical develops EXTEND, a neonatal support system that encloses extremely premature infants in a sterile, temperature‑controlled fluid‑filled environment for up to 28 days. By mimicking the fetal womb, the technology delays air exposure, allowing lungs and other organs to mature while providing continuous vital sign monitoring and automated fluid management, ultimately aiming to lower mortality and long‑term complications in NICU patients.